公开(公告)号：WO2019129679A1

公开(公告)日：2019-07-04

申请号：PCT/EP2018/086468

申请日：2018-12-21

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： BENZ, Joerg ,  DENGL, Stefan ,  FENN, Sebastian ,  MOELLEKEN, Joerg ,  EHLER, Andreas

IPC分类号： A61K39/395 ,  C07K16/22

CPC分类号： C07K16/22 ,  A61K39/39591 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to methods for improving anti-VEGF antibodies in order to provide or improve antibodies that preferentially inhibit binding to VEGF to VEGF-R2 rather than VEGF binding to VEGF-R1; and antibodies provided by said methods.

公开(公告)号：WO2019089147A1

公开(公告)日：2019-05-09

申请号：PCT/US2018/051806

申请日：2018-09-19

申请人： FIBROGEN, INC.

发明人： PORTER, Seth ,  LIPSON, Kenneth E. ,  GORINA de TRAVY, Eduard ,  YU, Kin-Hung Peony

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/22

CPC分类号： C07K16/22 ,  A61K2039/505 ,  A61P11/00 ,  C07K2317/24 ,  A61K2300/00

摘要： The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (IPF) by administering an anti-CTGF antibody. In particular, the treatment methods provided avoid toxicities associated with approved therapies and also avoid the attenuation of the efficacy of an anti-CTGF antibody caused by these approved therapies.

公开(公告)号：WO2019086394A1

公开(公告)日：2019-05-09

申请号：PCT/EP2018/079611

申请日：2018-10-30

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： GEORGES, Guy ,  PLATZER, Josef

IPC分类号： C07K16/22 ,  C07K16/46

CPC分类号： C07K16/468 ,  C07K16/22 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/73

摘要： Herein is reported a multimeric fusion polypeptide comprising five monomeric fusion polypeptides each comprising at least a Fab fragment and a COMP-domain of SEQ ID NO: 01 or a functional fragment thereof.

公开(公告)号：WO2018208670A1

公开(公告)日：2018-11-15

申请号：PCT/US2018/031386

申请日：2018-05-07

申请人： TRUSTEES OF TUFTS COLLEGE

发明人： HOFFMAN, Andrew M.

IPC分类号： A61K35/51 ,  A61K35/28 ,  C12N5/0775 ,  C07K16/22

CPC分类号： A61K38/1841 ,  A61K35/28 ,  A61K35/51 ,  C07K16/22 ,  C07K2317/76 ,  C12N5/0665 ,  C12N2501/15 ,  C12N2510/04 ,  G01N33/5076

摘要： Provided are mesenchymal stromal cell (MSC)-derived extracellular vesicles (EV) having tethered (membrane-bound) TGF-β (MSC-derived membrane-tethered TGF-β EV), and compositions containing such EV for use as therapeutics and immunomodulatory agents. Provided also are diagnostic methods and methods of assessing or monitoring disease status and/or progression in patients using membrane-tethered TGF-β derived from a variety of cell sources that serve as detectable, quantifiable biomarkers in biological samples. The MSC-derived membrane-tethered TGF-β EV can also be used to deliver various bioactive agents to a target cell or tissue for treating various diseases. The level of TGF-β tethered to the membrane of the EV can also be modified or manipulated in vitro or ex vivo. Such modified MSC-derived membrane-tethered TGF-β EV are useful as immunotherapeutic agents in the treatment or management of certain diseases, particularly those involving inflammation, autoimmunity, transplant rejection and cancer.

公开(公告)号：WO2018122053A1

公开(公告)日：2018-07-05

申请号：PCT/EP2017083630

申请日：2017-12-19

申请人： HOFFMANN LA ROCHE ,  HOFFMANN LA ROCHE

发明人： ADLER MICHAEL ,  SCHOENHAMMER KARIN

IPC分类号： A61K39/395 ,  A61K47/18 ,  A61K47/26 ,  C07K16/22 ,  C07K16/46

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  C07K16/468 ,  C07K2317/76

摘要： This invention relates to a stable pharmaceutical formulation of an antibody against Angiopoietin-2, in particular a bispecific antibody binding Angiopoietin-2 and vascular endothelial growth factor, and a process for the preparation and uses of the formulation.

公开(公告)号：WO2018119001A1

公开(公告)日：2018-06-28

申请号：PCT/US2017/067432

申请日：2017-12-19

申请人： FRED HUTCHINSON CANCER RESEARCH CENTER

发明人： OLSON, James ,  MHYRE, Andrew, J. ,  CORRENTI, Colin

IPC分类号： A61K38/06 ,  A61K38/16 ,  C07K14/00

CPC分类号： A61K47/6871 ,  A61K38/00 ,  A61K47/6811 ,  A61K47/6851 ,  A61K47/6881 ,  A61P25/28 ,  A61P35/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/50

摘要： Peptide-antibody complexes, including fusions and conjugates, that target or accumulate in target cells, such as tumors and diseased cells, or enhance the immune system are disclosed. In some embodiments, such complexes function as platforms for attaching and targeting one or more therapeutic agents or detectable agents, including radioisotopes, detectable labels, and/or cytotoxic agents, to target cells in the central nervous system or across the blood brain barrier, cancerous cells, or target cells recognized by the antibody in such complexes. In some complexes, the peptide serves as the targeting mechanism, while other embodiments contemplate the antibody as the targeting mechanism. Peptides and/or antibodies can be engineered to deliver various effector functions in various embodiments. Peptide-antibody complexes that function as immunotherapies and enhance a body's immune system in detecting and/or destroying diseased cells or pathogens are also disclosed. Pharmaceutical compositions and uses of peptide-antibody complexes are further disclosed.

公开(公告)号：WO2017214706A1

公开(公告)日：2017-12-21

申请号：PCT/CA2017/000148

申请日：2017-06-14

申请人： TISSUE REGENERATION THERAPEUTICS INC.

发明人： ESTRADA VALLEJO, Catalina ,  DAVIES, John E.

IPC分类号： A61K35/51 ,  A61K31/713 ,  A61K38/17 ,  A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  A61P35/00 ,  C07K14/47 ,  C07K14/52 ,  C07K14/78 ,  C07K16/22 ,  C07K16/28 ,  C12N15/113 ,  C12N5/077 ,  C12N5/10

CPC分类号： A61K35/51 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/18 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/21 ,  A61K38/212 ,  A61K38/22 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61P35/00 ,  C07K14/52 ,  C07K14/78 ,  C07K16/22 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C12N5/0665 ,  C12N5/069 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2510/00

摘要： Herein described is a method for treating cancer in a subject by administering a human umbilical cord perivascular cell (HUCPVC) that has been genetically modified to increase the expression of an oligonucleotide or a polypeptide such as an anti-cancer antibody.

摘要翻译： 本文描述了一种通过施用经遗传修饰以增加寡核苷酸或多肽如抗血管生成素的表达的人脐带血管周细胞（HUCPVC）来治疗受试者的癌症的方法， 癌症抗体。

公开(公告)号：WO2017189899A1

公开(公告)日：2017-11-02

申请号：PCT/US2017/029930

申请日：2017-04-27

申请人： IMMUNICOM, INC.

发明人： JOSEPHS, Steven F. ,  JAFRI, Amir ,  MAHANT, Vijay

IPC分类号： A61K39/395 ,  A61K31/715 ,  A61K31/737 ,  A61M1/34 ,  A61M1/36 ,  A61M1/30

CPC分类号： C07K16/22 ,  A61M1/3486 ,  A61M1/3679

摘要： Embodiments disclosed herein relate to devices and methods for removing, depeleting, reducing or decreasing TGFβ polypeptides from blood or a blood product.

摘要翻译： 本文公开的实施方案涉及用于从血液或血液产品去除，减少，减少或减少TGFβ多肽的装置和方法。

公开(公告)号：WO2017147408A1

公开(公告)日：2017-08-31

申请号：PCT/US2017/019334

申请日：2017-02-24

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： CHUTE, John, P. ,  HIMBURG, Heather, A.

IPC分类号： C07K16/22 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61K31/7088 ,  A61K38/02

CPC分类号： A61K31/7088 ,  A61K31/17 ,  A61K31/4745 ,  A61K31/519 ,  A61K31/52 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/706 ,  A61K31/7076 ,  A61K38/18 ,  A61K45/06 ,  A61P35/02 ,  C07K16/22 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

摘要： Provided herein are methods of treating hematologic cancer, such as chronic myelogenous leukemia, or splenomegaly by inhibiting PTN expression or activity. Additionally, provided herein are methods of reducing white blood cell count in a subject with elevated white blood cell count (e.g., as a result of a pathological condition), as well as methods of reducing the number of leukemia stem cells in bone marrow by inhibiting PTN expression or activity.

摘要翻译： 本文提供通过抑制PTN表达或活性来治疗血液癌症例如慢性粒细胞性白血病或脾肿大的方法。 此外，本文提供了降低具有升高的白细胞计数（例如，由于病理状态）的受试者中的白细胞计数的方法，以及通过抑制骨髓中白血病干细胞的数量 PTN表达或活性。

公开(公告)号：WO2017147182A1

公开(公告)日：2017-08-31

申请号：PCT/US2017/018938

申请日：2017-02-22

申请人： ACCELERON PHARMA INC.

发明人： KUMAR, Ravindra ,  ALIMZHANOV, Marat ,  PEARSALL, Robert, Scott

IPC分类号： C07K16/46 ,  C07K16/18 ,  C07K2/00 ,  C07K19/00 ,  A61K39/395 ,  A61K38/02 ,  A61P37/00 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  A61K2300/00

摘要： Disclosed herein are ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an ActRII antagonists and a PDl-PDLl antagonist.

摘要翻译： 本文公开了用于增加需要其的患者（包括例如癌症患者）中的免疫应答和/或活性的ActRII拮抗剂和方法。 在一些实施方案中，本公开涉及用于治疗患者的癌症和/或肿瘤的方法，其包括施用ActRII拮抗剂和PD1-PDL1拮抗剂。